Production Of Human Monoclonal Antibodies In Vitro
Funder
National Health and Medical Research Council
Funding Amount
$358,500.00
Summary
Antibodies are defence molecules that permeate our tissues. The diversity of antibodies in a healthy organism is vast, providing the potential to neutralise almost any biological molecule or pathogen with exquisite selectivity. We have invented a cell culture-based platform to generate and select human antibodies specific for any desired target. Unlike most antibodies currently used in laboratories, these antibodies will be usable as drugs as well as for detection of disease.
A Universal Prophylactic Vaccine For Hepatitis C Virus
Funder
National Health and Medical Research Council
Funding Amount
$643,337.00
Summary
Hepatitis C Virus (HCV) infects 200 million people world wide. An effective vaccine to prevent HCV is urgently needed but must afford protection against the 7 diverse genotypes. In this project grant we aim to further define the quality of the immune response that is generated by a novel HCV vaccine candidate that generates pan-genotypic immunity, its unique structural features, and methods of manufacturing so that it can be tested in a future phase I human clinical trial.
Developing Functionalised Microbubbles For Molecular Ultrasound Imaging And Targeted Delivery Of Drugs And MicroRNA Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$677,229.00
Summary
We aim to develop gas-filled microbubbles that are directed to markers of thrombosis and inflammation and will allow visualisation of blood clots and early inflammatory reactions via ultrasound. This will allow early and timely treatment. We will systematically test for the best method of microbubble coating with recombinant antibodies in various animal models of thrombosis and inflammation. In addition, we plan to load microbubbles with drugs and target these to areas where they are needed.
Development Of An Immunotherapy Against Kgp Of Porphyromonas Gingivalis
Funder
National Health and Medical Research Council
Funding Amount
$495,710.00
Summary
Chronic periodontitis is an inflammatory disease of the supporting tissues of the teeth associated with specific bacteria, which results in the destruction of tooth support and ultimately leads to tooth loss. This project aims to develop an immunotherapy against the major virulence factor produced by bacteria associated with the disease. The immunotherapy will be evaluated in animal models of disease.
A New Scrambled Antigen Vaccine (SAVINE) Approach: Proof-of-concept In Non-human Primates For HIV-1
Funder
National Health and Medical Research Council
Funding Amount
$120,700.00
Summary
The specific aim of this proposal is to demonstrate, in non-human primates, proof–of-concept of a patented new platform vaccine technology (scrambled antigen vaccine or SAVINE) designed to encode all the protein sequences of an infectious agent, in this case HIV-1. These are arranged as equal-sized, overlapping fragments such that all potential T cell epitopes that are needed to induce broad T-cell-mediated immunity are maintained. The synthetically designed vaccine uses consensus sequences of H ....The specific aim of this proposal is to demonstrate, in non-human primates, proof–of-concept of a patented new platform vaccine technology (scrambled antigen vaccine or SAVINE) designed to encode all the protein sequences of an infectious agent, in this case HIV-1. These are arranged as equal-sized, overlapping fragments such that all potential T cell epitopes that are needed to induce broad T-cell-mediated immunity are maintained. The synthetically designed vaccine uses consensus sequences of HIV-1 to provide universal coverage of the major HIV-1 strains for a global population. The synthetic systematically designed HIV-1 vaccine will be delivered using our newly developed prime-boost immunisation regime that induces particularly high levels of cell-mediated immunity.Read moreRead less